Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study

OBJECTIVE: Verinurad (RDEA3170) is a high-affinity, selective URAT1 inhibitor in development for treating gout and asymptomatic hyperuricaemia. This study evaluated the pharmacodynamics, pharmacokinetics and safety of verinurad in combination with febuxostat in adults with gout. METHODS: The phase I...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Roy, Winkle, Peter, Hall, Jesse, Valdez, Shakti, Liu, Sha, Yan, Xiaohong, Hicks, Liz, Lee, Caroline, Miner, Jeffrey N, Gillen, Michael, Hernandez-Illas, Martha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Crystal Arthropathies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892780/
https://www.ncbi.nlm.nih.gov/pubmed/29657831
http://dx.doi.org/10.1136/rmdopen-2018-000647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5892780/
https://www.ncbi.nlm.nih.gov/pubmed/29657831
http://dx.doi.org/10.1136/rmdopen-2018-000647

Ejemplares similares